Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional studyJianqiu Wu, Jifeng Feng, Yongping Song et al.|BMC Cancer|2016Cited by 32
Allogeneic double‐negative T cell therapy for relapsed <scp>acute myeloid leukemia</scp> patients post <scp>allogeneic hematopoietic stem cell transplantation</scp>: A first‐in‐human phase I studyBaolin Tang, Xiaoyu Zhu, Ping Qiang et al.|American Journal of Hematology|2022Cited by 26
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open‐label studyLijuan Deng, Jun Zhu, Zhiming Li et al.|American Journal of Hematology|2023Cited by 18
Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia PatientsDaobin Zhou, Xiangyang Zhang, Jie Jin et al.|Blood|2021Cited by 11
Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up ResultsXinxin Cao, Daobin Zhou, Jie Jin et al.|Blood|2023Cited by 4